Pfizer Inc. (PFE) Stake Lowered by Cabot Wealth Management

Cabot Wealth Management cut its stake in Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,314 shares of the biopharmaceutical company’s stock after selling 55 shares during the period. Cabot Wealth Management’s holdings in Pfizer were worth $268,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Janus Capital Management boosted its position in shares of Pfizer by 35.2% in the third quarter. Janus Capital Management now owns 11,561,514 shares of the biopharmaceutical company’s stock valued at $363,157,000 after buying an additional 3,012,704 shares in the last quarter. Atalanta Sosnoff Capital boosted its stake in Pfizer by 12.1% in the fourth quarter. Atalanta Sosnoff Capital now owns 1,935,494 shares of the biopharmaceutical company’s stock valued at $62,478,000 after buying an additional 209,124 shares during the period. Verde Servico Internacionais bought a new stake in Pfizer during the fourth quarter valued at $24,213,000. Creative Planning boosted its stake in Pfizer by 15.7% in the fourth quarter. Creative Planning now owns 660,706 shares of the biopharmaceutical company’s stock valued at $21,328,000 after buying an additional 89,688 shares during the period. Finally, Nexus Investment Management boosted its stake in Pfizer by 0.7% in the fourth quarter. Nexus Investment Management now owns 622,970 shares of the biopharmaceutical company’s stock valued at $20,109,000 after buying an additional 4,085 shares during the period.

Shares of Pfizer Inc. (NYSE:PFE) opened at 30.49 on Friday. Pfizer Inc. has a 1-year low of $28.47 and a 1-year high of $36.46. The firm’s 50 day moving average price is $31.56 and its 200-day moving average price is $33.11. The company has a market capitalization of $188.21 billion and a P/E ratio of 22.89.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.09. The firm had revenue of $12.10 billion for the quarter, compared to the consensus estimate of $11.56 billion. Pfizer’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.57 EPS. Analysts expect that Pfizer Inc. will post $2.19 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 2nd. Stockholders of record on Friday, February 5th will be given a dividend of $0.30 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.24. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.94%. The ex-dividend date is Wednesday, February 3rd.

Several analysts recently weighed in on the stock. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Independent Research GmbH reiterated a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a report on Wednesday, October 28th. SP Equity Research reiterated a “hold” rating and issued a $40.00 price target on shares of Pfizer in a report on Wednesday, October 28th. Nord/LB reiterated a “buy” rating on shares of Pfizer in a report on Tuesday. Finally, Cowen and Company reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a report on Wednesday, December 2nd. Six analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

This story was originally published by EMQ (http://www.emqtv.com) and is the sole property of EMQ. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.emqtv.com/pfizer-inc-pfe-stake-lowered-by-cabot-wealth-management/177570/

Receive News Ratings for Pfizer Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Tags:

Saturday, January 30th, 2016 EN

No comments yet.

Leave a comment

You must be logged in to post a comment.